CCRA Introduction to Certified Clinical Research Associate 3 — Questions and Answers
Question 1: During a monitoring visit, the CRA finds that the investigator site file (ISF) is missing the latest protocol amendment signed by the PI. What action should the CRA take?
- Document the missing document as a finding and request that the site obtain and file it promptly (Correct answer)
- Immediately terminate the site from the study
- Ignore the issue if the PI verbally confirms awareness of the amendment
- File the document on behalf of the site without notifying the sponsor
Correct answer: Document the missing document as a finding and request that the site obtain and file it promptly
A missing signed protocol amendment in the ISF is a documentation deficiency that must be documented in the monitoring report and remediated by the site.
Question 2: What is the role of the Data Safety Monitoring Board (DSMB) in a clinical trial?
- To independently review accumulating safety and efficacy data and recommend continuation, modification, or termination of the trial (Correct answer)
- To approve the protocol before the trial begins
- To conduct site inspections on behalf of the FDA
- To manage the randomization schedule for subjects
Correct answer: To independently review accumulating safety and efficacy data and recommend continuation, modification, or termination of the trial
A DSMB is an independent committee that periodically reviews unblinded data to protect the safety of trial participants and the validity of the trial.
Question 3: Which regulation requires sponsors to promptly review all information relevant to the safety of the investigational drug received from any source?
- 21 CFR 312.32 (Correct answer)
- 21 CFR 50.25
- 45 CFR 46.111
- 21 CFR 56.107
Correct answer: 21 CFR 312.32
21 CFR 312.32 specifically governs IND safety reports and requires sponsors to review all safety information and report serious unexpected adverse drug reactions.
Question 4: A Phase I clinical trial primarily evaluates:
- Safety, tolerability, pharmacokinetics, and maximum tolerated dose in a small group of subjects (Correct answer)
- Efficacy compared to placebo in a large patient population
- Long-term safety over several years in post-marketing surveillance
- Comparative effectiveness of two approved drugs
Correct answer: Safety, tolerability, pharmacokinetics, and maximum tolerated dose in a small group of subjects
Phase I trials focus on safety, tolerability, PK/PD properties, and dose escalation, typically in 20–100 healthy volunteers or patients.
Question 5: What is the meaning of 'blinding' (or 'masking') in a clinical trial?
- A procedure to prevent participants and/or investigators from knowing which treatment is being administered (Correct answer)
- The process of randomizing subjects into treatment arms
- A method to exclude subjects who do not meet eligibility criteria
- The statistical analysis plan for handling missing data
Correct answer: A procedure to prevent participants and/or investigators from knowing which treatment is being administered
Blinding prevents knowledge of treatment assignment to reduce bias; single-blind masks the subject, while double-blind masks both subject and investigator.
Question 6: An informed consent form must be written at a reading level that is understandable to the subject. According to FDA guidance, this is generally at approximately what grade level?
- 6th to 8th grade reading level (Correct answer)
- 12th grade reading level
- College undergraduate level
- Medical professional level
Correct answer: 6th to 8th grade reading level
FDA guidance recommends that consent forms be written at a 6th to 8th grade reading level to ensure comprehension by the general population.
Question 7: What is a 'protocol deviation' versus a 'protocol violation' in clinical research?
- A deviation is a minor, unplanned departure from the protocol; a violation is a more serious departure that may affect subject safety or data integrity (Correct answer)
- A deviation requires FDA reporting; a violation does not
- A violation is always intentional, while a deviation is always accidental
- They are interchangeable terms with no meaningful distinction
Correct answer: A deviation is a minor, unplanned departure from the protocol; a violation is a more serious departure that may affect subject safety or data integrity
Deviations are minor unplanned departures from the protocol, while violations are serious departures that may impact subject safety or data validity and require prompt reporting.
CCRA Introduction to Certified Clinical Research Associate 3
During a monitoring visit, the CRA finds that the investigator site file (ISF) is missing the latest protocol amendment signed by the PI.
What action should the CRA take?